JW Shinyak will issue 15 billion won in unsecured privately placed convertible bonds to raise funds for debt repayment. The convertible bonds have a conversion price of 3,000 won and a coupon rate of 4.7%; conversion will result in the issuance of 5 million common shares. The bon
2026-05-21
A new framework, CAML, that explains the basis for medical artificial intelligence (AI) decisions has been developed and published in a Nature sister journal (IF 26.7). The technology visualizes the AI’s decision-making process by separating decisive patterns from individual back
2026-05-21
JW Shinyak will issue 15 billion won in hybrid securities to repay debt. The privately placed bonds will have a 30-year maturity and a 4.7% coupon rate, with a step-up provision taking effect five years after issuance. All proceeds will be used to repay debt, with the aim of impr
2026-05-21
Anxiety and obsessive-compulsive disorders, which affect 1% to 4.4% of the global population, have been linked to calcium signaling in the brain’s immune cells, known as microglia. Activating calcium signaling in mouse microglia using optogenetic technology induced anxiety-like b
2026-05-21
A Chinese research team has developed a nanotherapy that effectively reverses metabolic dysfunction-associated steatotic liver disease (MASLD), which affects more than one-third of adults worldwide. The treatment precisely blocks a key pathway in MASLD progression by using nanopa
2026-05-21
‘Senescence’ in patients’ T cells has been identified as a cause of CAR-T therapy failure in half of patients. Up to 80% of T cells in patients aged 55 and older were senescent and had low proliferative capacity, resulting in higher treatment failure rates; this was also confirme
2026-05-21
Canadian researchers have developed a high-speed synthesis platform that reduces the synthesis of nucleic acid analogs from the several months previously required to a single step, leading to the identification of three new compounds with anti-HIV activity. The platform uses a “c
2026-05-21
A triple combination therapy for patients with unresectable hepatocellular carcinoma achieved an objective response rate of 75% and a disease control rate of 95%, converting 17.5% of patients to a resectable state. The regimen combined hepatic arterial infusion chemotherapy (HAIC
2026-05-21
Mywell Bio’s denosumab biosimilar has received approval in China for two additional indications, including bone metastases from solid tumors. The biosimilar demonstrated equivalence to the reference drug in a phase 3 trial and has signed supply agreements with 33 countries, inclu
2026-05-21
A Stanford University research team has developed a programmable cytokine called “trikine” that links three receptors to enhance anticancer activity, unlike conventional approaches that bind two receptors. The technology combines signals from IL-2 and IL-21 to strengthen T-cell k
2026-05-21
